跳转至内容
Merck

D-007

Supelco

Desmethyldoxepin solution

cis/trans, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C18H19NO
CAS号:
分子量:
265.35
MDL號碼:
分類程式碼代碼:
41116107
PubChem物質ID:
NACRES:
NA.24

等級

certified reference material

形狀

liquid

特點

Snap-N-Spike®/Snap-N-Shoot®

包裝

ampule of 1 mL

製造商/商標名

Cerilliant®

濃度

1.0 mg/mL in methanol

技術

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

應用

clinical testing

格式

single component solution

儲存溫度

−20°C

SMILES 字串

CNCC/C=C1C2=C(C=CC=C2)COC3=C/1C=CC=C3

InChI

1S/C18H19NO/c1-19-12-6-10-16-15-8-3-2-7-14(15)13-20-18-11-5-4-9-17(16)18/h2-5,7-11,19H,6,12-13H2,1H3/b16-10-

InChI 密鑰

HVKCEFHNSNZIHO-YBEGLDIGSA-N

一般說明

Desmethyldoxpein is the primary urinary metabolite of doxepin, a tricyclic antidepressant used for the treatment of sleep maintenance and sold under trade names such as Silenor® and Aponal. This analytical reference standard is suited for use in LC/MS or GC/MS methods for urine drug testing, clinical toxicology, and forensic analysis applications.

應用

Desmethyldoxepin solution may be used as an internal standard in the high performance liquid chromatographic (HPLC) determination of bupivacaine in samples of human serum.

法律資訊

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Silenor is a registered trademark of Somaxon Pharmaceuticals, Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

訊號詞

Danger

危險分類

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

標靶器官

Eyes

儲存類別代碼

3 - Flammable liquids

水污染物質分類(WGK)

WGK 2

閃點(°F)

49.5 °F - closed cup

閃點(°C)

9.7 °C - closed cup


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

High-performance liquid chromatographic determination of bupivacaine in human serum
Lindberg.P.L.R
Journal of Chromatography. B, Biomedical Sciences and Applications, 309, 369-374 (1984)
Robert Schomburg et al.
Journal of neural transmission (Vienna, Austria : 1996), 118(4), 641-645 (2011-02-26)
Doxepin--like other antidepressant drugs (ADs)--shows a variable antidepressant effect in clinical practice. The cause for this variability is as yet unclear; however, pharmacokinetic factors such as the variable permeability of doxepin into the cerebrospinal fluid (CSF), may contribute to the
K K Midha et al.
European journal of clinical pharmacology, 42(5), 539-544 (1992-01-01)
Commercial preparations of the tricyclic anti-depressant doxepin contain 15% of the more active cis-doxepin and 85% of the trans-isomer. The single dose pharmacokinetics of doxepin and its major metabolite N-desmethyldoxepin were examined in 30 healthy young men. Results for total
Heinz-Werner Hagedorn et al.
Journal of pharmaceutical and biomedical analysis, 29(1-2), 317-323 (2002-06-14)
Due to its tranquilizing properties, the tricyclic antidepressant doxepin may be misused as a doping agent in competition horses. Therefore, efficient analytical procedures are required to detect this drug in samples submitted for doping control. To screen for parent doxepin
M Meyer-Barner et al.
European journal of clinical pharmacology, 58(4), 253-257 (2002-07-24)
Little information on the population pharmacokinetics of the tricyclic antidepressant doxepine and its pharmacologically active metabolite desmethyldoxepine is available. However, a more individualised drug therapy may be feasible if the influence of various patient characteristics on plasma concentration was known.

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门